Fluorodeoxyglucose Positron Emission Tomography Studies in the Diagnosis and Staging of Transitional Cell Carcinoma

  • I. Jenna Liu
  • George M. Segall
  • Matilde Nino-Murcia
  • Martha K. Terris

Abstract

The introduction of positron emission tomography (PET) has allowed scientists and clinicians to measure biochemical and physiological processes in vivo. Although PET has been in existence since the 1960s, it did not gain complete clinical acceptance until roughly a decade ago. At that time, Di Chiro et al demonstrated the ability of PET to differentiate between recurrent brain tumor and radiation necrosis.5 This prompted the recognition of PET as a valid method of tumor imaging.

Keywords

Catheter Hydration Lymphoma Attenuation Pneumonia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bachor R, Kocher F, Gropengiesser F, Reske SN, Hautmann RE: Positron emission tomography: Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results. Urologe A, 34:138, 1995.PubMedGoogle Scholar
  2. 2.
    Bakheet SM, Powe J, Ezzat A, Al Suhaibani H, Tulbah A, Rostom A: F-18 FDG whole-body positron emission tomography scan in primary breast sarcoma. Clin Nucl Med, 23:604, 1998.PubMedCrossRefGoogle Scholar
  3. 3.
    Buy J-N, Moss A, Guinet C, Ghossain MA, Malbec L, Arrive L, et al: MR staging of bladder carcinoma: Correlation with pathologic findings. Radiology, 169:695, 1988.PubMedGoogle Scholar
  4. 4.
    Graeber GM, Gupta NC, Murray GF: Positron emission tomographic imaging with fluoro-deoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg, 117:719, 1999.PubMedCrossRefGoogle Scholar
  5. 5.
    Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, et al: PET in Oncology: Will it replace the other modalities? Semin Nucl Med, 27:94, 1997.PubMedCrossRefGoogle Scholar
  6. 6.
    Hoh CK, Seltzer MA, Franklin F, DeKernion JB, Phelps ME, Belldegrun A: Positron emission tomography in urological oncology. J Urol, 159:347, 1998.PubMedCrossRefGoogle Scholar
  7. 7.
    Kole AC, Nieweg OE, van Ginkel RJ, Pruim J, Hoekstra HJ, Paans AM, et al: Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose. Ann Surg Oncol, 4:57, 1997.PubMedCrossRefGoogle Scholar
  8. 8.
    Kosuda S, Kison P, Greenough R, Grossman B, Wahl R: Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med, 24:615, 1997.PubMedGoogle Scholar
  9. 9.
    Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al: Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol, 4:613, 1997.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • I. Jenna Liu
    • 1
    • 2
    • 3
  • George M. Segall
    • 1
    • 2
    • 3
  • Matilde Nino-Murcia
    • 1
    • 2
    • 3
  • Martha K. Terris
    • 1
    • 2
    • 3
  1. 1.Sections of Urology, Nuclear Medicine, and RadiologyVeterans Affairs Palo Alto Health Care SystemPalo Alto
  2. 2.Department of UrologyStanford University Medical CenterStanford
  3. 3.Department of BiologyCase Western Reserve UniversityCleveland

Personalised recommendations